- Home
- ADAG vs PAVS Comparison
ADAG vs PAVS Comparison
Compare ADAG & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAG
- PAVS
- Stock Information
- Founded
- ADAG 2011
- PAVS 2004
- Country
- ADAG China
- PAVS United States
- Employees
- ADAG N/A
- PAVS N/A
- Industry
- ADAG Biotechnology: Pharmaceutical Preparations
- PAVS Medicinal Chemicals and Botanical Products
- Sector
- ADAG Health Care
- PAVS Health Care
- Exchange
- ADAG Nasdaq
- PAVS Nasdaq
- Market Cap
- ADAG 91.4M
- PAVS 89.6M
- IPO Year
- ADAG 2021
- PAVS 2019
- Fundamental
- Price
- ADAG $1.88
- PAVS $0.90
- Analyst Decision
- ADAG Strong Buy
- PAVS
- Analyst Count
- ADAG 1
- PAVS 0
- Target Price
- ADAG $8.00
- PAVS N/A
- AVG Volume (30 Days)
- ADAG 83.0K
- PAVS 4.1K
- Earning Date
- ADAG 07-24-2025
- PAVS 07-31-2025
- Dividend Yield
- ADAG N/A
- PAVS N/A
- EPS Growth
- ADAG N/A
- PAVS N/A
- EPS
- ADAG N/A
- PAVS N/A
- Revenue
- ADAG $103,204.00
- PAVS $6,613,273.00
- Revenue This Year
- ADAG $6,488.89
- PAVS N/A
- Revenue Next Year
- ADAG $57.50
- PAVS N/A
- P/E Ratio
- ADAG N/A
- PAVS N/A
- Revenue Growth
- ADAG N/A
- PAVS 2.50
- 52 Week Low
- ADAG $1.33
- PAVS $0.32
- 52 Week High
- ADAG $3.58
- PAVS $1.50
- Technical
- Relative Strength Index (RSI)
- ADAG 49.43
- PAVS 46.29
- Support Level
- ADAG $1.74
- PAVS $0.83
- Resistance Level
- ADAG $1.98
- PAVS $0.94
- Average True Range (ATR)
- ADAG 0.11
- PAVS 0.03
- MACD
- ADAG -0.01
- PAVS 0.01
- Stochastic Oscillator
- ADAG 38.89
- PAVS 49.40
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.